Charles Dumontet
YOU?
Author Swipe
View article: DIS3 licenses B cells for plasma cell differentiation in humans
DIS3 licenses B cells for plasma cell differentiation in humans Open
DIS3 is the main catalytic subunit of the nuclear RNA exosome, a complex playing a crucial role in RNA processing and the degradation of various noncoding RNA substrates. In mice, DIS3 is essential for genomic rearrangements during B cell …
View article: Exploring and bypassing resistance to targeted therapies in colorectal cancer
Exploring and bypassing resistance to targeted therapies in colorectal cancer Open
Colorectal cancer (CRC) remains a leading cause of cancer-related deaths globally, though targeted therapies have transformed treatment and brought renewed hope. However, resistance to these therapies is a persistent challenge, driven by g…
View article: Whole-Exome Sequencing-Based Linkage Analysis of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS) Pedigrees
Whole-Exome Sequencing-Based Linkage Analysis of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS) Pedigrees Open
Background/Objectives: Family history is a known risk factor for multiple myeloma (MM) and its precursor condition, monoclonal gammopathy of undetermined significance (MGUS). Previous genome-wide association studies (GWASs) have identified…
View article: Beyond Rodents: Alternative Animal Models in Colorectal Cancer Research
Beyond Rodents: Alternative Animal Models in Colorectal Cancer Research Open
Colorectal cancer (CRC) is the third most common cancer worldwide, imposing a significant burden on public health. Despite the use of various therapeutic strategies, the prognosis for patients with metastatic and drug-resistant CRC remains…
View article: Netrin‐1 and B‐cell maturation antigen expression in a large cohort of 361 lymphomas: sensitive and specific staining in plasmablastic lymphomas, and therapeutic perspectives
Netrin‐1 and B‐cell maturation antigen expression in a large cohort of 361 lymphomas: sensitive and specific staining in plasmablastic lymphomas, and therapeutic perspectives Open
Netrin‐1 and B‐cell maturation antigen (BCMA) are currently being evaluated as therapeutic targets in oncology. However, studies investigating their expression in mature human lymphoid malignancies are sparse. This study aimed to investiga…
View article: 80P A systemically administered innate immune modulator displays potent anti-tumor activity against metastatic osteosarcoma
80P A systemically administered innate immune modulator displays potent anti-tumor activity against metastatic osteosarcoma Open
View article: The synergy between alkylating agents and ERCC1–XPF inhibitors is p53 dependent
The synergy between alkylating agents and ERCC1–XPF inhibitors is p53 dependent Open
Background DNA repair plays a major role in maintaining genomic stability, thus limiting the transformation of normal cells into cancer cells. However, in cancer patients treated with DNA‐targeting drugs, DNA repair can decrease efficacy b…
View article: End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapy
End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapy Open
Background In spite of spectacular advances in the treatment of multiple myeloma, a majority of patients will die from this disease or related complications. While a great amount of focus has been dedicated to the development of novel ther…
View article: Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma
Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma Open
Despite several approved therapies, multiple myeloma (MM) remains an incurable disease with high unmet medical need. “Off-the-shelf” T-cell bispecific antibodies (TCBs) targeting B-cell maturation antigen (BCMA) and G protein–coupled recep…
View article: Unlocking the potential of bio-inspired bioinks: A collective breakthrough in mammalian tissue bioprinting
Unlocking the potential of bio-inspired bioinks: A collective breakthrough in mammalian tissue bioprinting Open
View article: The landscape of rare genetic variants in familial Waldenström macroglobulinemia
The landscape of rare genetic variants in familial Waldenström macroglobulinemia Open
Waldenström macroglobulinemia (WM) is a rare hematological malignancy. Risk for WM is elevated 20-fold among first-degree relatives of patients with WM. However, the list of variants and genes that cause WM remains incomplete. In this stud…
View article: Unlocking the potential of bio-inspired bioinks: A collective breakthrough in mammalian tissue bioprinting
Unlocking the potential of bio-inspired bioinks: A collective breakthrough in mammalian tissue bioprinting Open
The composition of soft tissues in mammals can be simplified as approximately 60–65% water, 16% protein, 16% fat, 1% carbohydrate, and trillions of cells. This report brings together the collaborative efforts of 10 research groups over the…
View article: Combined effects of exercise and immuno-chemotherapy treatments on tumor growth in MC38 colorectal cancer-bearing mice
Combined effects of exercise and immuno-chemotherapy treatments on tumor growth in MC38 colorectal cancer-bearing mice Open
Acute exercise induces transient modifications in the tumor microenvironment and has been linked to reduced tumor growth along with increased infiltration of immune cells within the tumor in mouse models. In this study, we aimed to evaluat…
View article: A TLR4 Agonist Induces Osteosarcoma Regression by Inducing an Antitumor Immune Response and Reprogramming M2 Macrophages to M1 Macrophages
A TLR4 Agonist Induces Osteosarcoma Regression by Inducing an Antitumor Immune Response and Reprogramming M2 Macrophages to M1 Macrophages Open
Osteosarcoma (OsA) has limited treatment options and stagnant 5-year survival rates. Its immune microenvironment is characterized by a predominance of tumor-associated macrophages (TAMs), whose role in OsA progression remain unclear. Never…
View article: Identification of novel genetic loci for risk of multiple myeloma by functional annotation
Identification of novel genetic loci for risk of multiple myeloma by functional annotation Open
View article: Identification of novel genetic loci for risk of multiple myeloma by functional annotation
Identification of novel genetic loci for risk of multiple myeloma by functional annotation Open
View article: Contribution of Mesenchymal Stem Cells from Obese Adipose Tissue to PD-L1 Over-Expression and Breast Cancer Progression through Pathogenic Th17 Cell Activation
Contribution of Mesenchymal Stem Cells from Obese Adipose Tissue to PD-L1 Over-Expression and Breast Cancer Progression through Pathogenic Th17 Cell Activation Open
Background: Obesity is a well-known risk factor for cancer. We have previously reported the role of adipose-tissue-derived mesenchymal stem cells from obese individuals (ob-ASC) in the promotion of pathogenic Th17 cells and immune check po…
View article: Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization
Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization Open
Multiple myeloma (MM) arises following malignant proliferation of plasma cells in the bone marrow, that secrete high amounts of specific monoclonal immunoglobulins or light chains, resulting in the massive production of unfolded or misfold…
View article: A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical models
A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical models Open
Bacterial lipopolysaccharides (LPS) are potent innate immunostimulants targeting the Toll-like receptor 4 (TLR4), an attractive and validated target for immunostimulation in cancer therapy. Although LPS possess anti-tumor activity, toxicit…
View article: Supplementary Data from <i>In Vivo</i> Syngeneic Tumor Models with Acquired Resistance to Anti–PD-1/PD-L1 Therapies
Supplementary Data from <i>In Vivo</i> Syngeneic Tumor Models with Acquired Resistance to Anti–PD-1/PD-L1 Therapies Open
Supplementary Data from In Vivo Syngeneic Tumor Models with Acquired Resistance to Anti–PD-1/PD-L1 Therapies
View article: Data from <i>In Vivo</i> Syngeneic Tumor Models with Acquired Resistance to Anti–PD-1/PD-L1 Therapies
Data from <i>In Vivo</i> Syngeneic Tumor Models with Acquired Resistance to Anti–PD-1/PD-L1 Therapies Open
Antibodies targeting PD-1 and PD-L1 have produced durable responses in a subset of patients with cancer. However, a majority of these patients will ultimately relapse due to acquired resistance. To explore the underlying mechanisms of this…
View article: Supplementary Data from <i>In Vivo</i> Syngeneic Tumor Models with Acquired Resistance to Anti–PD-1/PD-L1 Therapies
Supplementary Data from <i>In Vivo</i> Syngeneic Tumor Models with Acquired Resistance to Anti–PD-1/PD-L1 Therapies Open
Supplementary Data from In Vivo Syngeneic Tumor Models with Acquired Resistance to Anti–PD-1/PD-L1 Therapies
View article: Data from <i>In Vivo</i> Syngeneic Tumor Models with Acquired Resistance to Anti–PD-1/PD-L1 Therapies
Data from <i>In Vivo</i> Syngeneic Tumor Models with Acquired Resistance to Anti–PD-1/PD-L1 Therapies Open
Antibodies targeting PD-1 and PD-L1 have produced durable responses in a subset of patients with cancer. However, a majority of these patients will ultimately relapse due to acquired resistance. To explore the underlying mechanisms of this…
View article: Supplementary Figure 1 from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models
Supplementary Figure 1 from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models Open
PDF file - 62K, Internalization of GA101 (black squares), rituximab (open diamonds), and ofatumumab (open triangles) upon binding to (A) SU-DHL4 cells and (B, C) whole blood derived from two CLL patients. Samples were incubated for 0.5, 2,…
View article: Supplementary Figure Legend from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models
Supplementary Figure Legend from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models Open
PDF file - 43K
View article: Supplementary Figure 2 from Pegfilgrastim Enhances the Antitumor Effect of Therapeutic Monoclonal Antibodies
Supplementary Figure 2 from Pegfilgrastim Enhances the Antitumor Effect of Therapeutic Monoclonal Antibodies Open
The tumor growth inhibition (TGI) was calculated on day 59 and 69 for untreated group and treated groups, respectively. The control group was sacrificed at day 59 as the tumor reached the maximum tolerated tumor size (2000 mm3) and the tre…
View article: Data from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models
Data from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models Open
We report the first preclinical in vitro and in vivo comparison of GA101 (obinutuzumab), a novel glycoengineered type II CD20 monoclonal antibody, with rituximab and ofatumumab, the two currently approved type I CD20 antibodi…
View article: Supplementary Video Legend from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models
Supplementary Video Legend from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models Open
PDF file - 39K
View article: Supplementary Methods from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models
Supplementary Methods from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models Open
PDF file - 100K
View article: Supplementary figure legends from Pegfilgrastim Enhances the Antitumor Effect of Therapeutic Monoclonal Antibodies
Supplementary figure legends from Pegfilgrastim Enhances the Antitumor Effect of Therapeutic Monoclonal Antibodies Open
Supplementary figure legends for supplementary figures 1,2 and 3